IMNM
Immunome, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-14/100
Last price
19.37
▲ 0.06 (0.31%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
19.64
Prev close
19.31
Day high
19.56
Day low
18.94
Volume
260.28K
Market cap
$2.29B
P/E (TTM)
—
52W range
13.49 – 30.06
Day trading desk
Gap from prior close
+1.71%
Prior close 19.31
VWAP
19.39
-0.13% from price
Relative volume
0.22×
Quiet session
Session range
3.71%
18.94 – 19.64
Position in range
62%
Mid range
ATR (14D)
1.18
6.08% of price
Prior day high
21.43
PDH
Prior day low
18.92
PDL
Bid / ask spread
—
Quote not published
Session volume
260.23K
Avg 1.21M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-9.95%
-11.5%
1M
-27.75%
-28.9%
3M
-19.86%
-22.9%
6M
-10.74%
-25.3%
YTD
-9.82%
-23.4%
1Y
+34.42%
+19.1%
3Y
+136.22%
+55.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on IMNM open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+25.25K
Net buying
Buy transactions
16
731.26K shares
Sell transactions
11
706.01K shares
Net transactions
+27
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
7.18M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 11, 26 | HIGGINS JACK Officer |
STOCK | 8.80K | $0 | Direct |
| Sep 11, 26 | HIGGINS JACK Officer |
SELL | 13.20K | $334.22K | Direct |
| Sep 11, 26 | HIGGINS JACK Officer |
CONVERSION | 18.00K | $24.30K | Direct |
| Aug 12, 26 | BARCHAS ISAAC Director |
SELL | 83.46K | $2.20M | |
| Aug 7, 26 | BARCHAS ISAAC Director |
SELL | 36.09K | $940.45K | Indirect |
| Aug 4, 26 | HORN KINNEY Officer |
SELL | 90.62K | $2.27M | Direct |
| Aug 4, 26 | HORN KINNEY Officer |
CONVERSION | 90.62K | $1.08M | Direct |
| Jul 23, 26 | STONEMAN SANDRA G. General Counsel |
STOCK | 38.25K | $0 | Direct |
| Jul 23, 26 | HORN KINNEY Officer |
STOCK | 31.25K | $0 | Direct |
| Jul 23, 26 | SIEGALL CLAY B Chief Executive Officer |
STOCK | 180.00K | $0 | Direct |
| Jul 23, 26 | ROSETT MAX Chief Financial Officer |
STOCK | 47.25K | $0 | Direct |
| Jul 23, 26 | HIGGINS JACK Officer |
STOCK | 38.25K | $0 | Direct |
| Jul 23, 26 | LECHLEIDER ROBERT Officer |
STOCK | 54.00K | $0 | Direct |
| Jul 23, 26 | TSAI PHILIP S. L. Chief Technology Officer |
STOCK | 38.25K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARCHAS ISAAC |
Director | — | Sale |
BIENAIME JEAN-JACQUES |
Director | 43.41K | Purchase |
HIGGINS JACK |
Officer | 59.25K | Stock Gift |
HORN KINNEY |
Officer | 0 | Sale |
LECHLEIDER ROBERT |
Officer | 69.81K | Stock Award(Grant) |
ROSETT MAX |
Chief Financial Officer | 101.29K | Stock Award(Grant) |
SIEGALL CLAY B |
Chief Executive Officer | 870.70K | Stock Award(Grant) |
STONEMAN SANDRA G. |
General Counsel | 43.80K | Stock Award(Grant) |
TSAI PHILIP S. L. |
Chief Technology Officer | 81.55K | Stock Award(Grant) |
WAGENHEIM PHILIP R |
Director | 341.15K | Sale |
Fundamentals
Market cap$2.29B
Enterprise value$1.68B
Revenue (TTM)$0
Gross profit$-206.23M
EBITDA$-257.69M
Net income$-254.32M
EPS (TTM)$-2.52
Free cash flow$-143.66M
Total cash$520.00M
Total debt$4.74M
Book value / share$4.63
Shares outstanding118.00M
Float108.66M
Short % of float16.72%
Dividend yield0.00%
Beta (5Y)2.56
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.98
PEG ratio—
Price / sales—
Price / book4.18
EV / revenue—
EV / EBITDA-6.51
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-64.03%
Return on assets-37.79%
Debt / equity0.90
Current ratio15.08
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $6.94M | $9.04M | $14.02M | $0 | -23.2% |
| Operating revenue | $6.94M | $9.04M | $14.02M | $0 | -23.2% |
| Research & development | $187.29M | $129.54M | $23.09M | $23.27M | +44.6% |
| Selling, general & admin | $43.77M | $32.95M | $19.66M | $13.63M | +32.8% |
| Total operating expense | $231.05M | $162.50M | $42.75M | $36.90M | +42.2% |
| Operating income | -$224.11M | -$153.46M | -$28.73M | -$36.90M | -46.0% |
| Net interest income | $11.72M | $12.84M | $2.72M | $5.00K | -8.7% |
| Pre-tax income | -$212.39M | -$292.96M | -$106.81M | -$36.90M | +27.5% |
| Net income | -$212.39M | -$292.96M | -$106.81M | -$36.90M | +27.5% |
| Net income to common | -$212.39M | -$292.96M | -$106.81M | -$37.52M | +27.5% |
| Basic EPS | -2.43 | -5.00 | -5.38 | -3.09 | +51.4% |
| Diluted EPS | -2.43 | -5.00 | -5.38 | -3.09 | +51.4% |
| EBIT | -$224.11M | -$153.46M | -$28.73M | -$36.90M | -46.0% |
| EBITDA | -$221.16M | -$151.35M | -$28.00M | -$36.27M | -46.1% |
| Basic shares | 87.35M | 58.64M | 19.84M | 12.13M | +49.0% |
| Diluted shares | 87.35M | 58.64M | 19.84M | 12.13M | +49.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $653.48M | $143.35M | $98.68M | $20.32M | — | +355.9% |
| Cash & short-term investments | $653.48M | $217.30M | $138.14M | $20.32M | — | +200.7% |
| Accounts receivable | — | — | — | $847.00K | $0 | — |
| Total current assets | $660.78M | $221.34M | $144.70M | $22.65M | — | +198.5% |
| Property, plant & equipment | $17.61M | $14.39M | $3.64M | $965.00K | — | +22.4% |
| Total assets | $683.19M | $240.24M | $148.54M | $24.05M | — | +184.4% |
| Total current liabilities | $44.99M | $54.31M | $21.83M | $7.33M | — | -17.2% |
| Total debt | $3.85M | $4.83M | $1.65M | $291.00K | — | -20.2% |
| Total liabilities | $48.84M | $59.08M | $28.66M | $7.39M | — | -17.3% |
| Retained earnings | -$728.16M | -$515.77M | -$222.81M | -$116.00M | — | -41.2% |
| Shareholder equity | $634.34M | $181.16M | $119.88M | $16.65M | — | +250.1% |
| Working capital | $615.79M | $167.03M | $122.87M | $15.32M | — | +268.7% |
| Net tangible assets | $634.34M | $181.16M | $119.88M | $16.65M | — | +250.1% |
| Shares issued | 113.13M | 64.46M | 43.25M | 12.13M | — | +75.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$212.39M | -$292.96M | -$106.81M | -$36.90M | +27.5% |
| Depreciation & amortisation | $2.96M | $2.10M | $728.00K | $631.00K | +40.6% |
| Stock-based compensation | $25.69M | $15.75M | $6.22M | $5.33M | +63.1% |
| Change in working capital | -$15.23M | $14.87M | $12.00M | $2.24M | -202.4% |
| Operating cash flow | -$190.92M | -$110.79M | -$7.57M | -$28.69M | -72.3% |
| Capital expenditure | -$15.93M | -$53.51M | -$831.00K | -$248.00K | +70.2% |
| Investing cash flow | $60.80M | -$85.06M | -$30.48M | -$248.00K | +171.5% |
| Financing cash flow | $640.36M | $240.53M | $116.41M | $32.00K | +166.2% |
| Free cash flow | -$206.85M | -$164.30M | -$8.40M | -$28.94M | -25.9% |
| End cash position | $653.69M | $143.45M | $98.78M | $20.42M | +355.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $4.01M | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $4.01M | — | — |
| Research & development | $59.88M | $46.38M | $60.77M | $49.19M | $40.45M | — | +29.1% |
| Selling, general & admin | $18.25M | $12.95M | $12.09M | $10.95M | $10.04M | — | +40.9% |
| Total operating expense | $78.14M | $59.33M | $72.86M | $60.14M | $50.49M | — | +31.7% |
| Operating income | -$78.14M | -$59.33M | -$72.86M | -$60.14M | -$46.48M | — | -31.7% |
| Net interest income | $5.01M | $5.49M | $2.96M | $2.68M | $3.08M | — | -8.8% |
| Pre-tax income | -$73.13M | -$53.84M | -$69.90M | -$57.46M | -$43.40M | — | -35.8% |
| Net income | -$73.13M | -$53.84M | -$69.90M | -$57.46M | -$43.40M | — | -35.8% |
| Net income to common | -$73.13M | -$53.84M | -$69.90M | -$57.46M | -$43.40M | — | -35.8% |
| Basic EPS | -0.65 | -0.48 | — | -0.65 | -0.50 | -0.52 | -35.4% |
| Diluted EPS | -0.65 | -0.48 | — | -0.65 | -0.50 | -0.52 | -35.4% |
| EBIT | -$78.14M | -$59.33M | -$72.86M | -$60.14M | -$46.48M | — | -31.7% |
| EBITDA | -$76.97M | -$58.58M | -$72.08M | -$59.41M | -$45.76M | — | -31.4% |
| Basic shares | 113.27M | 113.14M | — | 87.96M | 87.01M | 79.41M | +0.1% |
| Diluted shares | 113.27M | 113.14M | — | 87.96M | 87.01M | 79.41M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $217.71M | $582.69M | $653.48M | $272.64M | $143.88M | -62.6% |
| Cash & short-term investments | $520.00M | $582.69M | $653.48M | $272.64M | $268.04M | -10.8% |
| Total current assets | $538.45M | $594.31M | $660.78M | $279.92M | $277.43M | -9.4% |
| Property, plant & equipment | $21.30M | $19.91M | $17.61M | $14.69M | $14.29M | +7.0% |
| Total assets | $565.38M | $619.79M | $683.19M | $299.38M | $296.29M | -8.8% |
| Total current liabilities | $35.71M | $27.41M | $44.99M | $31.45M | $22.88M | +30.3% |
| Total debt | $4.74M | $3.69M | $3.85M | $4.01M | $4.14M | +28.3% |
| Total liabilities | $40.30M | $31.11M | $48.84M | $35.46M | $27.02M | +29.6% |
| Retained earnings | -$855.13M | -$782.00M | -$728.16M | -$658.26M | -$600.81M | -9.4% |
| Shareholder equity | $525.08M | $588.69M | $634.34M | $263.92M | $269.27M | -10.8% |
| Working capital | $502.74M | $566.90M | $615.79M | $248.48M | $254.55M | -11.3% |
| Net tangible assets | $525.08M | $588.69M | $634.34M | $263.92M | $269.27M | -10.8% |
| Shares issued | 113.40M | 113.17M | 113.13M | 91.71M | 87.01M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$73.13M | -$53.84M | -$69.90M | -$57.46M | -$43.40M | -35.8% |
| Depreciation & amortisation | $1.16M | $753.00K | $776.00K | $733.00K | $720.00K | +54.2% |
| Stock-based compensation | $8.80M | $7.95M | $7.89M | $6.75M | $5.35M | +10.6% |
| Change in working capital | $1.92M | -$13.58M | $3.22M | $10.33M | -$11.76M | +114.1% |
| Operating cash flow | -$61.69M | -$58.64M | -$47.95M | -$40.51M | -$49.40M | -5.2% |
| Capital expenditure | -$2.18M | -$12.02M | -$4.00M | -$1.12M | -$905.00K | +81.9% |
| Investing cash flow | -$304.35M | -$12.02M | -$4.00M | $123.88M | -$64.17M | -2,432.9% |
| Financing cash flow | $1.06M | -$135.00K | $432.80M | $45.39M | -$55.00K | +883.7% |
| Free cash flow | -$63.87M | -$70.65M | -$51.95M | -$41.63M | -$50.31M | +9.6% |
| End cash position | $217.92M | $582.90M | $653.69M | $272.85M | $144.09M | -62.6% |
Options analytics
Put / call volume
1.15
Put-heavy session
Put / call open interest
0.42
Positioning, not flow
Max pain
23.00
+18.7% from spot
ATM implied vol
79.7%
Nearest strike to spot
Skew (10% OTM)
-88.7%
Calls bid over puts
Call volume
119
Contracts, this expiry
Put volume
137
Contracts, this expiry
Heaviest call OI
25.00
695 contracts
Heaviest put OI
23.00
143 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.50 | -0.65 | -28.8% |
| Mar 2026 | -0.54 | — | — |
| Dec 2025 | -0.57 | -0.76 | -32.8% |
| Sep 2025 | -0.54 | -0.65 | -19.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.59 | 14 | $142.86K | 0.0% |
| Next quarter | -0.61 | 14 | $142.86K | 0.0% |
| Current year | -2.29 | 13 | $285.71K | -95.9% |
| Next year | -2.43 | 12 | $53.85M | +18,748.0% |
Analyst targets & ownership
Mean target$35.20
High target$40.00
Low target$24.00
Implied upside81.72%
Analyst count15
ConsensusSTRONG BUY
Strong buy / Buy3 / 12
Hold1
Sell / Strong sell0 / 0
Held by insiders6.32%
Held by institutions102.83%
Institutions holding287
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
21.05
-7.97% from price
SMA 20
22.75
-14.86% from price
SMA 50
25.09
-22.80% from price
SMA 100
23.08
-16.09% from price
SMA 200
22.74
-14.82% from price
EMA 12
21.46
-9.76% from price
EMA 26
23.01
-15.81% from price
EMA 50
23.74
-18.39% from price
RSI (14)
27.4
Oversold
MACD (12,26,9)
-1.54
Hist -0.35
ATR (14)
1.18
6.08% of price
Realised vol 30D
47.3%
Annualised
Bollinger upper
26.53
20, 2σ
Bollinger lower
18.98
20, 2σ
50 / 200 cross
Golden
25.09 vs 22.74
Trend bias
Below 200
-14.82%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.60
More volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
47.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-35.3%
Peak to trough
Max drawdown 5Y
-90.6%
Peak to trough
ATR 14
1.18
6.08% of price
Beta (reported)
2.56
5Y monthly, from filing
Short interest
Shares short
16.24M
Prior 17.39M
Change vs prior
-6.6%
Shorts covering
% of float
16.72%
Elevated
% of shares out
14.30%
Against total outstanding
Days to cover
15.7
Crowded exit
Float
108.66M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | Stifel | INITIATED | — | Hold |
| Sep 21, 26 | Alliance Global Partners | INITIATED | — | Buy |
| Sep 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 12, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 12, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jul 21, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jun 12, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| May 28, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| May 28, 26 | Barclays | INITIATED | — | Overweight |
| May 15, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| May 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 4, 26 | Craig-Hallum | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-05
Corporate Changes & Voting Matters
8-K · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-06-12
Periodic Financial Reports
10-Q · 2026-05-12
Proxy Statements
DEF 14A · 2026-04-24
Periodic Financial Reports
10-K · 2026-03-03
Corporate Changes & Voting Matters
8-K · 2025-12-15
Periodic Financial Reports
10-Q · 2025-11-06
Headlines
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 20h ago
Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed?
Simply Wall St. · 5d ago
Stifel Initiates Immunome at Hold With $24 Price Target
MT Newswires · 6d ago
Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run Continues
Simply Wall St. · 6d ago
Immunome Gets FDA Clearance for IM-1340 Clinical Trial in Advanced Solid Tumors
MT Newswires · 7d ago
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Business Wire · 7d ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 29d ago
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Business Wire · 35d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.